Hyaluronic Acid - Administration & dosage
Research News and Information

Saturday, November 21, 2009

Medial knee joint loading increases in those who respond to hyaluronan injection for medial knee osteoarthritis.

30 Oct 2009 Knee osteoarthritis (OA) is a cause of decline in function and the medial compartment is often affected. Intraarticular injection of hyaluronic acid (HA) is indicated as a symptom modifying treatment with at least 6 months passing between ... Read more...

The filler revolution: a six-year retrospective.

29 Sep 2009 There are currently more than 20 FDA-approved fillers in the United States (U.S.), noteworthy considering that it was only six years ago that the first hyaluronic acid filler was approved. The pace of development of filler substances in the last few ... Read more...

Critical organ preservation in reirradiation brachytherapy by injectable spacer.

29 Sep 2009 PURPOSE: This case series study evaluated the feasibility and effectiveness of an interstitial high-dose rate brachytherapy (HDR-BT) procedure combined with an at-risk organ-sparing procedure. METHODS AND MATERIALS: Thirty patients who were ... Read more...

Latest indexed articles for 'Hyaluronic Acid - Administration & dosage'

These are the very latest articles for this heading:

• Medial knee joint loading increases in those who respond to hyaluronan injection for medial knee osteoarthritis. 30 Oct 2009
• The filler revolution: a six-year retrospective. 29 Sep 2009
• Editorial comment. 29 Sep 2009
• Critical organ preservation in reirradiation brachytherapy by injectable spacer. 29 Sep 2009
• Targeted delivery of chemotherapeutic agents using improved radiosensitive liquid core microcapsules and assessment of their antitumor effect. 29 Sep 2009
• Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. 6 Sep 2009
• A split-face comparison of a new hyaluronic acid facial filler containing pre-incorporated lidocaine versus a standard hyaluronic acid facial filler in the treatment of naso-labial folds. 30 Aug 2009
• Volumizing effects of a smooth, highly cohesive, viscous 20-mg/mL hyaluronic acid volumizing filler: prospective European study. 25 Aug 2009
• Risk factors for urinary tract infection after dextranomer/hyaluronic acid endoscopic injection. 16 Aug 2009
• Editorial comment. 16 Aug 2009
• Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. 3 Aug 2009
• Air-assisted manual deep anterior lamellar keratoplasty for treatment of herpetic corneal scars. 30 Jul 2009
• Editorial comment. 20 Jul 2009
• Is availability of endoscopy changing initial management of vesicoureteral reflux? 20 Jul 2009
• Periurethral non-animal stabilized hyaluronic acid/dextranomer injections: efficacy and formation of granuloma/sterile abscess. 6 Jul 2009
• Microbiologic assessment of multidose Restylane for facial augmentation. 29 Jun 2009
• Osteoarthritis: Hyaluronic acid is not effective in symptomatic hip OA. 29 Jun 2009
• Surgical technique for small-incision intraocular lens exchange. 29 Jun 2009
• A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). 15 Jun 2009
• [Importance of local skin treatments during radiotherapy for prevention and treatment of radio-induced epithelitis] 10 Jun 2009

See a longer list of these articles.

Technical information about 'Hyaluronic Acid'

Definition: A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.

Chemical name: Hyaluronic acid

Registry Number: 9004-61-9

Descriptor UI: D006820

Alternative terms: Hyaluronic Acid; Acid, Hyaluronic; Amvisc; Bausch and Lomb Brand of Sodium Hyaluronate; Biolon; Akorn, Inc. Brand of Sodium Hyaluronate; Etamucine; Hyaluronan; Hyvisc; Anika Therapeutics Brand of Sodium Hyaluronidate; Luronit; Sodium Hyaluronate; Hyaluronate, Sodium; Hyaluronate Sodium; Amo Vitrax; Vitrax, Amo; Advanced Medical Optics, Inc. Brand of Sodium Hyaluronate; Healon; Advanced Medical Optics Brand of Sodium Hyaluronidate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Viscosupplements; Adjuvants, Immunologic;

Tree Number: D09.698.373.475;

History Note: 2002; for BIOLON use POLYMETHYL METHACRYLATE 1977-2001